These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34275563)

  • 1. Association between homocysteine and third ventricle dilatation, mesencephalic area atrophy in Parkinson's disease with cognitive impairment.
    Fu XY; Zhang YC; Ding CW; Yang M; Song X; Wang CS; Chen XF; Zhang Y; Sheng YJ; Mao P; Mao CJ; Liu CF
    J Clin Neurosci; 2021 Aug; 90():273-278. PubMed ID: 34275563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
    Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
    Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study.
    Rodriguez-Oroz MC; Lage PM; Sanchez-Mut J; Lamet I; Pagonabarraga J; Toledo JB; García-Garcia D; Clavero P; Samaranch L; Irurzun C; Matsubara JM; Irigoien J; Bescos E; Kulisevsky J; Pérez-Tur J; Obeso JA
    Mov Disord; 2009 Jul; 24(10):1437-44. PubMed ID: 19452554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.
    Sapkota S; Gee M; Sabino J; Emery D; Camicioli R
    Mov Disord; 2014 Mar; 29(3):368-74. PubMed ID: 24395213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.
    Zoccolella S; Lamberti P; Iliceto G; Diroma C; Armenise E; Defazio G; Lamberti SV; Fraddosio A; de Mari M; Livrea P
    Clin Chem Lab Med; 2005; 43(10):1107-10. PubMed ID: 16197306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of homocysteine, folate, and white matter hyperintensities in Parkinson's patients with different motor phenotypes.
    Shen Y; Dong ZF; Pan PL; Xu G; Huang JY; Liu CF
    Neurol Sci; 2019 Sep; 40(9):1855-1863. PubMed ID: 31055730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third ventricular width by transcranial sonography is associated with cognitive impairment in Parkinson's disease.
    Gao HL; Qu Y; Chen SC; Yang QM; Li JY; Tao AY; Mao ZJ; Xue Z
    CNS Neurosci Ther; 2024 Feb; 30(2):e14360. PubMed ID: 37448105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesencephalic area measured by transcranial sonography in the differential diagnosis of parkinsonism.
    Sastre-Bataller I; Vázquez JF; Martínez-Torres I; Sahuquillo P; Rubio-Agustí I; Burguera JA; Ferrer JM; Valero C; Tembl JI
    Parkinsonism Relat Disord; 2013 Aug; 19(8):732-6. PubMed ID: 23684370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations between blood lipid, serum cystatin C, and homocysteine levels in patients with Parkinson's disease.
    Li J; Gu C; Zhu M; Li D; Chen L; Zhu X
    Psychogeriatrics; 2020 Mar; 20(2):180-188. PubMed ID: 31828903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third ventricular width assessed by transcranial ultrasound correlates with cognitive performance in Parkinson's disease.
    Behnke S; Pilotto A; Liepelt-Scarfone I; Yilmaz R; Pausch C; Dieterich S; Bürmann J; Spiegel J; Dillmann U; Unger M; Posner I; Berg D
    Parkinsonism Relat Disord; 2019 Sep; 66():68-73. PubMed ID: 31324557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midbrain area for differentiating Parkinson's disease from progressive supranuclear palsy.
    Ghourchian S; Mousavi A; Zamani B; Shahidi G; Rohani M
    Clin Neurol Neurosurg; 2019 Aug; 183():105383. PubMed ID: 31181432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
    Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
    Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression features of serum Cystatin C and homocysteine of Parkinson's disease with mild cognitive dysfunction.
    Chen WW; Cheng X; Zhang X; Zhang QS; Sun HQ; Huang WJ; Xie ZY
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):2957-63. PubMed ID: 26367713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
    Camicioli RM; Bouchard TP; Somerville MJ
    Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.
    O'Suilleabhain PE; Sung V; Hernandez C; Lacritz L; Dewey RB; Bottiglieri T; Diaz-Arrastia R
    Arch Neurol; 2004 Jun; 61(6):865-8. PubMed ID: 15210523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma homocysteine, folate and vitamin B12 levels in Parkinson's disease in China: A meta-analysis.
    Dong B; Wu R
    Clin Neurol Neurosurg; 2020 Jan; 188():105587. PubMed ID: 31733593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum homocysteine and physical exercise in patients with Parkinson's disease.
    Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
    Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis.
    Xie Y; Feng H; Peng S; Xiao J; Zhang J
    Neurosci Lett; 2017 Jan; 636():190-195. PubMed ID: 27840145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Width of the third ventricle assessed by transcranial sonography can monitor brain atrophy in a time- and cost-effective manner--results from a longitudinal study on 500 subjects.
    Wollenweber FA; Schomburg R; Probst M; Schneider V; Hiry T; Ochsenfeld A; Mueller M; Dillmann U; Fassbender K; Behnke S
    Psychiatry Res; 2011 Mar; 191(3):212-6. PubMed ID: 21288698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson's Disease.
    Sleeman I; Lawson RA; Yarnall AJ; Duncan GW; Johnston F; Khoo TK; Burn DJ
    J Parkinsons Dis; 2019; 9(2):351-359. PubMed ID: 30909247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.